Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transformer-Based Deep Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients.

Blood purification·2026
Same author

Increased Risk of Intraocular Pressure-Lowering Treatment in Patients with End-Stage Renal Disease Undergoing Hemodialysis.

Ophthalmology. Glaucoma·2026
Same author

Cutaneous Microvascular Functional Reserve is Associated with Kidney Function and Histopathologic Injury in CKD: The MAP-CKD Study.

medRxiv : the preprint server for health sciences·2026
Same author

Physical Activity Fragmentation and All-Cause Mortality in Hemodialysis Patients: Insights From Fitbit Study.

Kidney medicine·2026
Same author

A Survey Study To Assess the Diversity and Inclusion in Nephrology Journal Editorial Leadership.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Associations of Biomarkers of Kidney Tubule Health with Retinal Microvascular Signs: The Multi-Ethnic Study of Atherosclerosis.

Kidney360·2025

Related Experiment Videos

Recurrent IgG4 Disease-Related Tubulointerstitial Nephritis Treated With Rituximab As Maintenance Therapy.

Alejandro Valdesuso1, Jill Nehrbas2, Joseph Dan Khoa Nguyen3

  • 1Nephrology, University of Virginia, Charlottesville, USA.

Cureus
|June 1, 2026
PubMed
Summary

Immunoglobulin G4-related disease (IgG4-RD) can affect the kidneys. This case shows rituximab (RTX) retreatment is safe and effective for managing recurrent IgG4-related tubulointerstitial nephritis (IgG4-TIN) and improving renal function.

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

Keywords:
akiigg4 disease-related tubulointerstitial nephritisigg4-related diseaserituximabtubulo-interstitial nephritis

Related Experiment Videos

  • Immunoglobulin G4-related disease (IgG4-RD) is a rare, chronic, immune-mediated condition affecting multiple organ systems.
  • Renal involvement in IgG4-RD commonly presents as IgG4-related tubulointerstitial nephritis (IgG4-TIN) or IgG4-related membranous nephropathy (IgG4-MN).
  • Standard treatment involves immunosuppressants like steroids and rituximab (RTX), which are effective for achieving remission.